Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Methylphenidate XR is a central nervous system (CNS) stimulant prescribed primarily for Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 and older, adolescents, and adults. It is the extended-release formulation of methylphenidate hydrochloride, designed to provide symptom control throughout the day with a single dose. Methylphenidate XR is available under multiple brand names including Concerta, Ritalin LA, Metadate CD, Aptensio XR, Adhansia XR, Jornay PM, QuilliChew ER, and Quillivant XR. Generic versions are also widely manufactured.
Methylphenidate XR works by blocking the reuptake of norepinephrine and dopamine into presynaptic neurons. This increases the concentration of these neurotransmitters in the synaptic cleft, which enhances attention, focus, and impulse control. The extended-release formulation uses various delivery mechanisms (osmotic release, biphasic beads, or delayed release) to provide a gradual, sustained release of medication over 8 to 16 hours depending on the specific product.
The typical adult dose range is 18 mg to 72 mg once daily. Children usually start at 18 mg daily.
Methylphenidate XR has a findability score of 45 out of 100, meaning it is frequently difficult to find in stock. The FDA has listed Methylphenidate on its drug shortage list since July 2023, and shortages persist into 2026 for certain formulations and dosage strengths. While the DEA increased production quotas by up to 25% in October 2025, demand continues to outpace supply. Patients may need to call multiple pharmacies or use tools like Medfinder to locate available stock.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
As a Schedule II controlled substance, Methylphenidate XR can be prescribed by licensed physicians and other authorized prescribers. Common prescribing specialties include:
Telehealth prescribing is available for Methylphenidate XR, though DEA regulations may require an initial in-person visit or specific telehealth prescribing protocols for Schedule II controlled substances.
Yes, Methylphenidate XR is classified as a Schedule II controlled substance by the DEA. This is the highest schedule for medications with accepted medical use and means it has a high potential for abuse and dependence. Prescriptions cannot be called in — they must be written or sent electronically. Refills are not allowed; a new prescription is required each time. Most states limit prescriptions to a 30-day supply.
Serious side effects can include increased blood pressure, psychiatric symptoms (psychosis, mania, aggression), peripheral vasculopathy (Raynaud's phenomenon), seizures, and growth suppression in children with prolonged use. Methylphenidate XR carries a boxed warning regarding its high potential for abuse and dependence. Contact your doctor immediately if you experience chest pain, shortness of breath, or new psychiatric symptoms.
Talk to your doctor before switching medications, as each option has different benefits, side effects, and coverage considerations.
Always inform your doctor and pharmacist of all medications, supplements, and substances you are taking.
Methylphenidate XR remains one of the most widely prescribed ADHD medications, but ongoing shortages since 2023 continue to make it challenging for many patients to find in stock. With a findability score of 45, you may need to check multiple pharmacies or use a tool like Medfinder to locate available supply near you. Generic versions are significantly more affordable than brand-name options, and manufacturer savings programs like the Concerta Savings Card can bring costs down to as little as $4 per fill with commercial insurance. If you're struggling to find Methylphenidate XR, talk to your doctor about alternative formulations or medications that may be more readily available.
%2C%20Color%3DOriginal.png)
